{
  "outcomes_metadata": {
    "timestamp": "2025-10-01T11:07:10.421313",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "consolidation_type": "outcomes",
    "data_split": "test",
    "total_unique_outcomes": 124,
    "source_countries": [
      "AT",
      "BE",
      "CZ",
      "DE",
      "DK",
      "EN",
      "ES",
      "EU",
      "FR",
      "IT",
      "NL",
      "PO",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_outcomes": {
    "efficacy": {
      "survival_endpoints": [
        "overall survival (OS)",
        "all-cause mortality",
        "long-term survival",
        "median survival",
        "survival",
        "perioperative mortality",
        "treatment-related deaths",
        "treatment-related mortality",
        "mortality"
      ],
      "response_measures": [
        "objective response rate (ORR; RECIST 1.1)",
        "objective response rate (ORR; mRECIST for liver disease)",
        "objective response rate (ORR)",
        "tumor response rate",
        "tumour response rate",
        "response rates (RECIST criteria)",
        "response rates (mRECIST)",
        "response rates (RECIS systems)",
        "partial response (PR)",
        "complete response (CR)",
        "complete remission",
        "minor response (reduction of tumour size by 25 to 50%)",
        "stable disease (SD)",
        "stable disease (for at least 16 weeks)",
        "disease control rate (DCR)",
        "disease control rate (DCR; mRECIST)",
        "clinical benefit rate (CBR)",
        "clinical benefit rate",
        "disease control",
        "objective tumour response",
        "tumor reduction",
        "time to response",
        "duration of response (DoR)",
        "duration of response",
        "effectiveness of ablation (magnetic resonance imaging)",
        "effectiveness of ablation (multiphase computed tomography)",
        "completeness of ablation (multiphase computed tomography with contrast)",
        "completeness of ablation (magnetic resonance imaging with contrast)",
        "bridging therapy benefit",
        "reduction of progression",
        "number needed to treat (NNT)"
      ],
      "progression_measures": [
        "progression-free survival (PFS)",
        "progression-free survival (stratified log-rank)",
        "progression-free survivorship",
        "time to progression (TTP)",
        "time to progression",
        "time to progression of the tumor",
        "time to tumour progression",
        "time to radiological disease progression",
        "progression",
        "reduction of progression",
        "time to symptomatic progression (TTSP)",
        "time to symptomatic disease progression (FHSI-8 questionnaire)",
        "time to symptom progression",
        "time to deterioration",
        "time to clinically meaningful deterioration (EORTC QLQ-C30)",
        "time to clinically meaningful deterioration (EORTC QLQ-HCC18)",
        "early detection of local recurrence",
        "early detection of de novo tumor",
        "disease recurrence",
        "recurrence",
        "delay of recurrence"
      ]
    },
    "safety": {
      "adverse_events": [
        "adverse events (general)",
        "adverse events (graded according to the National Cancer Institute)",
        "adverse events (serious)",
        "serious adverse events",
        "adverse reactions (general)",
        "adverse events (Grade ≥ 3)",
        "grade 3 adverse reactions",
        "grade 4 adverse reactions",
        "treatment-emergent adverse events (TEAEs)",
        "adverse events (occurring in >10% of patients)",
        "toxicity",
        "side-effects (biopsy-related)",
        "complication incidence",
        "complications",
        "post-treatment complications",
        "serious complications",
        "long-term treatment-related complications",
        "undesirable effects",
        "intraoperative complications",
        "morbidity",
        "neurotoxicity",
        "hand-foot-skin reaction",
        "hand-foot skin reaction",
        "hand-foot syndrome",
        "skin rash",
        "rash",
        "skin desquamation",
        "desquamation",
        "fatigue",
        "diarrhoea",
        "nausea",
        "vomiting",
        "abdominal pain",
        "abdominal swelling (EORTC QLQ-HCC18)",
        "pain",
        "pain (EORTC QLQ-HCC18)",
        "joint pain",
        "back pain",
        "limb pain",
        "arthralgia",
        "myalgia",
        "muscle spasms",
        "headache",
        "fever",
        "fever (EORTC QLQ-HCC18)",
        "cough",
        "shortness of breath",
        "dyspnoea",
        "pleural effusion",
        "respiratory failure",
        "decreased appetite",
        "anorexia",
        "weight loss",
        "decreased weight",
        "hypody",
        "hypodynamia",
        "asthenia",
        "dysphonia",
        "dysgeusia",
        "dyspepsia",
        "dysphagia",
        "stomatitis",
        "dry skin",
        "erythema",
        "pruritus",
        "dermatitis exfoliative",
        "acne",
        "hyperkeratosis",
        "folliculitis",
        "alopecia",
        "keratoacanthoma",
        "squamous cell cancer of the skin",
        "secondary cancer",
        "infusion reactions",
        "infections",
        "sepsis",
        "influenza-like illness",
        "mucosal inflammation",
        "bleeding",
        "haemorrhage",
        "brain/gastrointestinal bleeding",
        "brain haemorrhage",
        "haemorrhagic events",
        "arterial thromboembolic events",
        "cerebral vascular accident",
        "cardiovascular arrest",
        "myocardial infarction",
        "myocardial ischaemia",
        "congestive heart failure",
        "hypertension",
        "arterial hypertension",
        "proteinuria",
        "renal adverse events",
        "renal failure",
        "hepatic encephalopathy",
        "hepatic insufficiency",
        "liver failure",
        "liver disorders",
        "intestinal failure",
        "gastrointestinal disorders",
        "gastro-oesophageal reflux disease",
        "increased alanine aminotransferase (ALT) activity",
        "transient increase in transaminases",
        "increased amylase",
        "increased lipase",
        "creatinine increase",
        "hypocalcaemia",
        "hypokalaemia",
        "hyponatraemia",
        "hypoglycaemia",
        "hyperthyroidism",
        "hypothyroidism",
        "diabetes mellitus",
        "depression",
        "peripheral sensory neuropathy",
        "tinnitus",
        "flushing",
        "rhinorrhoea",
        "edema",
        "lymphoedema",
        "lymphopenia",
        "leukopenia",
        "neutropenia",
        "anaemia",
        "thrombocytopenia",
        "portal vein thrombosis",
        "erectile dysfunction",
        "sudden death",
        "deaths"
      ],
      "serious_events": [
        "serious adverse events",
        "serious complications",
        "treatment-related deaths",
        "treatment-related mortality",
        "sudden death"
      ],
      "discontinuations": [
        "adverse events leading to discontinuation of treatment",
        "drug withdrawal due to adverse events",
        "dose modification due to adverse events",
        "dropout rate for toxicity",
        "discontinuation of treatment due to adverse events"
      ]
    },
    "quality_of_life": {
      "patient_reported_outcomes": [
        "EORTC QLQ-C30",
        "EORTC QLQ-HCC18",
        "EORTC QLQ-LC13",
        "EQ-5D",
        "EQ-5D-5L",
        "EQ-5D-3L",
        "EQ VAS (Euro QoL visual analogue scale)",
        "EQ-5D visual analogue scale",
        "European Quality of Life questionnaire",
        "FACT-G (Functional Assessment of Cancer Therapy – General)",
        "FACT-Hep",
        "FHSI-8 questionnaire",
        "health-related quality of life (HRQoL)",
        "overall quality of life (measured with a validated and reliable instrument)",
        "quality of life weights",
        "health state utility values"
      ],
      "functional_status": [
        "function scales (EORTC QLQ-C30)",
        "function scales (EORTC QLQ-HCC18)",
        "role functioning",
        "physical complaints",
        "psychosocial complaints",
        "emotional complaints",
        "social complaints",
        "spiritual complaints",
        "burden of disease"
      ],
      "symptom_measures": [
        "pain (EORTC QLQ-HCC18)",
        "jaundice (EORTC QLQ-HCC18)",
        "fever (EORTC QLQ-HCC18)",
        "abdominal swelling (EORTC QLQ-HCC18)",
        "nutrition",
        "body image",
        "distress (physical and psychological complaints)",
        "early detection of local recurrence",
        "early detection of de novo tumor",
        "deterioration in patient quality of life (EORTC QLQ-C30)",
        "deterioration in patient quality of life (EORTC QLQ-HCC18)"
      ]
    },
    "economic": {
      "cost_effectiveness": [
        "cost-effectiveness analysis",
        "cost-effectiveness (incremental cost-effectiveness ratio, ICER)",
        "cost per quality-adjusted life year (QALY)",
        "cost-benefit analysis"
      ],
      "utilities": [
        "quality-adjusted life years (QALYs)",
        "quality of life weights",
        "health state utility values"
      ],
      "resource_utilization": [
        "length of hospital stay",
        "days of missed work",
        "number needed to harm (NNH)"
      ]
    },
    "other": {
      "exploratory_endpoints": [
        "prognosis (BCLC staging system)",
        "diagnosis (multiphasic CT, MRI, CT and MRI Liver Imaging Reporting and Data System (LI-RADS) v2018, contrast-enhanced ultrasound)",
        "pathological examination",
        "histological parameters",
        "immunohistochemistry markers (for diagnosis, prognosis, subtypes)",
        "immunohistochemical confirmation of hepatocytic origin",
        "genetic tests (for metabolic diseases)",
        "genetic diagnosis",
        "molecular classification (by specific mutations)",
        "surveillance (abdominal ultrasound or multiphase cross-sectional imaging every 6 months, with or without alpha-fetoprotein evaluation)",
        "vital signs recording",
        "laboratory haematological testing",
        "laboratory biochemical testing",
        "urinalysis",
        "electrocardiography"
      ],
      "biomarkers": [
        "blood and tumour biomarkers correlated with clinical outcomes",
        "plasma pharmacokinetics lenvatinib exposure parameters",
        "pharmacokinetic parameters"
      ]
    }
  }
}